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 This project defines the utility of bulk RNA sequencing and single-cell RNA (scRNA) 
sequencing in characterizing the tumor microenvironment of pediatric medulloblastomas. 
Comparisons between the two methods can identify how they can be used to further define the 
understudied medulloblastoma. These comparisons were achieved through subtyping based on 
gene expression data and evaluating the immune expression of primary versus recurrent tumors. 
Our cohort consists of five medulloblastoma patients that underwent bulk RNA and scRNA 
sequencing. Bulk RNA sequencing was utilized to accurately subtype medulloblastomas using 
gene expression data. It was found that scRNA sequencing can further characterize 
medulloblastomas subtypes through the classification of distinct cell populations between group 
3 and group 4 medulloblastomas. Not only is robust subtyping possible, but scRNA sequencing 
can be used to identify cell types and their differential expression across several samples. 
Immune expression can also be analyzed through gene expression analysis and scRNA 
sequencing and is represented in this paper through the longitudinal study of a primary 
medulloblastoma versus a recurrent medulloblastoma in the same patient. Gene expression 
analysis using the PanCancer Immune Panel exhibited expression of immune genes as compared 
to other tumor types and identified under and overexpressed genes. Through scRNA sequencing, 
it was identified that in one case of a recurrent medulloblastoma, immune cell infiltration 
increased. These data and futures studies that utilize bulk and scRNA sequencing to characterize 
tumors can aide in designing immune therapies that give medulloblastoma patients the best 




In recent years, next generation sequencing has greatly increased our knowledge of 
genomic and transcriptomic alterations in pediatric central nervous system (CNS) tumors likely 
associated with tumorigenesis (Gröbner et al., 2018) (Ma et al., 2018). Despite these discoveries, 
there remains a critical need to develop new treatment paradigms that decrease recurrence of 
brain tumors, as these tumor types remain the leading cause of disease-related death in children 
(Curtin et al., 2016). Characterizing the tumor immune microenvironment has been at the 
forefront of many ongoing cancer research and drug development studies, as immunotherapy is 
considered one of the most promising treatments in cancer medicine today (Sharma & Allison, 
2015). Specifically, in pediatric CNS tumors, there is little known about the tumor immune 
microenvironment, especially given the apparent immune-privileged status of the CNS.  
Cancers are comprised of a complex collection of cell types including normal cells, 
stromal cells, malignant cells, and infiltrating immune cells, and it is this complexity that 
predisposes patients to inferior prognoses and possible resistance to treatment (Dagogo-Jack & 
Shaw, 2018). We typically characterize tumors and their infiltrating immune cells from 
traditional, “bulk” RNA sequencing data, that results from RNA extraction of the tumor mass 
and therefore includes all cell types. In particular, the gene expression profiles from bulk 
RNAseq can be used to characterize the different cellular components and in some cases, to 
provide additional subtyping information that may be pertinent to treatment or prognosis.   
Immune cell components can be evaluated by computational deconvolution approaches that 
essentially pattern match gene expression data to the known gene expression profiles for 
different immune cell types. However, this approach is somewhat limited in that it lacks 
resolution needed to distinguish all immune cell types and cannot provide information about 
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important immune cell states, such as T-cell exhaustion or activation.  This leads to the omission 
of critical differences about the immune microenvironment (Venteicher et al., 2017) that may be 
highly informative to physicians, in terms of likely response to certain therapies. In order to 
circumvent these challenges, single cell RNA sequencing (scRNAseq) has emerged as a 
powerful technique that reveals gene expression profiles of individual cells from dissociated 
tumor tissue and can be evaluated both from the perspective of teasing out tumor biology as well 
as identifying immune cells and their states. 
The most common brain cancer types in children are embryonal cancers, including 
medulloblastomas. Previous genomic studies of human medulloblastomas have defined four 
consensus molecular subgroups (SHH, WNT, Group 3, and Group 4) based on discrete genomic 
and transcriptomic alterations within the tumors (Taylor et al., 2012). A recent investigation from 
a research group at St. Jude Children’s Research Hospital analyzed single cell RNA-sequencing 
(scRNA-seq) from 25 pediatric medulloblastomas and revealed previously unknown differences 
between the subtypes of medulloblastomas, including cell types of origin from which the tumors 
arise within the brain (Hovestadt et al., 2019). However, the immune microenvironment in 
medulloblastomas remains understudied, especially in those children whose medulloblastomas 
recur following surgery and treatment, and thereby limits a long-term goal to implement 
immunotherapeutic strategies in the clinic. 
Here, we present a study based on RNA expression of single cells obtained from pediatric 
medulloblastoma samples, demonstrating that these data can be utilized to characterize the 
subtype of the tumor and to evaluate immune gene expression and, by inference, the presence or 
absence of different immune cell types in pediatric CNS tumors. Our analysis includes the 
evaluation of data from single cell studies of RNA expression, to provide subtyping information 
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and to explore the presence of immune cell populations in primary and recurrent 
medulloblastomas. In particular, Table 1 provides information regarding the five 
medulloblastomas studied using scRNAseq (Table 1).   
 




timepoint Diagnosis Brain region Sex Age 
CH79_P primary medulloblastoma group 4 fourth ventricle female 12 CH79_R recurrent medulloblastoma group 4 frontal lobe 17 
CH34 primary medulloblastoma group 4 posterior fossa/fourth ventricle male 8 
CH161 primary medulloblastoma group 4 posterior fossa male 6 





MATERIALS AND METHODS 
RNA extraction 
RNA was extracted from frozen brain tumor tissue using mirVana isolation kit (Thermo 
Fisher Scientific) according to the manufacturer’s protocol.  
Immune gene expression assay and analysis 
Multiplexed gene expression profiling was performed using the PanCancer Immune 
Profiling Panel (version 1.1) from NanoString Technologies, which assays expression of 770 
immune-related and housekeeping genes. This platform provides gene-specific probes that carry 
a unique sequence and are hybridized to tumor-extracted DNA under optimal hybridization 
conditions overnight. Subsequent hybridization of this mixture with sequence-specific 
fluorescent-labeled oligonucleotides followed by imaging on the nCounter instrument, provides 
quantitative expression for each of the 770 genes in the assay. Briefly, tumor-extracted RNA 
(150 ng) was prepped according to manufacturer’s protocol and analyzed on the nCounter 
instrument. Data were normalized using the housekeeping genes included in the panel. A 
category summary of the immune genes on the PanCancer panel is listed in Table 2. Differential 
expression was performed using the mean of each group to calculate a fold-change expression 
difference and by calculating an adjusted p-value (Benjamini false discovery rate) which corrects 
for multiple comparisons in a large, multiplexed gene expression dataset. 
 
Table 2. Summary of PanCancer immune gene categories. 
Category # of Genes Category # of Genes 
Chemokines 99 T-Cell Functions 72 
Cytokines 56 Adhesion 25 
Cell Functions 155 Complement 15 
B-Cell Functions 18 Senescence 12 
Antigen Processing 22 Interleukins 38 
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Regulation 154 Macrophage Functions 6 
Cytotoxicity 10 TLR 11 
NK Cell Functions 17 Microglial Functions 5 
Transporter Functions 22 TNF Superfamily 30 
Pathogen Defense 12 T-Cell Functions 72 
Cell Cycle 13 Adhesion 25 




Five samples of between 5-20 milligrams of surgically resected pediatric brain tumors 
underwent a nuclei isolation protocol (Table 2). Each sample was homogenized by douncing in 
nuclear isolation medium (NIM; sucrose: 0.25M, KCl: 25mM, MgCl2: 5mM, TrisCl: 10mM), 
dithiothreitol, and 50x propidium iodide. Following douncing, 10% Triton-X was added, and the 
samples were stained with 2 μL of a nuclear stain (Hoescht), allowing for the visualization of 
nuclei during cell sorting. Nuclei were gated based on Hoescht signal and sorted into batches for 
a total of 15,000 nuclei that were subsequently added into a master mix containing reagents for 
single nuclei capture and library preparation. Reverse transcriptase (RT) enzyme was added to 
each sample. These samples were loaded on a 10 X Genomics Chromium Controller in order to 
generate single cell Gel Bead-In Emulsions (GEMs), utilizing the single cell 3’reagent kit v2 
from 10x Genomics.  
Library preparation and sequencing 
Following preparation of the GEMs, single nuclei RNA sequencing libraries were 
prepared for next generation sequencing (NGS), following manufacturer instructions for the 
single cell 3’reagent kit v2 (10x Genomics). Briefly, the samples were amplified by 12 cycles of 
PCR during cDNA amplification based on a targeted recovery of >6,000 nuclei. After sample 
indexing, the final libraries underwent a number of PCR amplification cycles based on the cDNA 
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input (Table 3). Post-library construction quality control metrics were obtained using 1) Qubit 
quantitation to measure concentration of the final library and 2) Agilent TapeStation to evaluate 
the size of the final NGS library. Figure 1 shows a schematic of the final library product. Final 
libraries were pooled and sequenced as a five sample multiplex on an Illumina NovaSeq S1 flow 
cell. The run recipe is as follows: Read 1 – 28 cycles; i7 Index – 8 cycles; i5 Index – 0 cycles; 
Read 2 – 91 cycles. Table 3 provides the corresponding quality control and sequencing metrics. 
 















CH79_P 14 14.5 562 9209 19540 1846 
CH79_R 16 42.2 463 6513 51845 1460 
CH34 14 11.7 525 12634 13297 1307 
CH161 14 6 555 3715 54163 2117 
CH87 14 8.44 444 9466 21398 1835 
 
 
Figure 1. Schematic of final sequencing library. The Chromium Single Cell 3’ Gene 
Expression library is flanked with paired-end Illumina primers P5 and P7 (blue and gold, 
respectively). Encoded in Read 1 is the 10x Genomics barcode (green) which is unique and 
specific to each captured cell and the Unique Molecular Identifier (UMI, red) sequence which is 
unique to each originating library fragment. TruSeq Read 1 and TruSeq Read 2 (black) are 
Illumina primer sites used to initiate forward and reverse sequencing reactions. Poly(dT)VN 
(violet) is a poly(T) site used to capture poly(A) tails found in most human mRNAs. Read 2 
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sequences the cDNA insert. Each sample is indexed (grey). (Figure obtained from 10x Genomics 
Chromium Controller User Manual). 
 
Single nuclei sequencing analysis 
Data pre-processing, including alignment, filtering, barcode-based sorting, and unique 
molecular identifier (UMI) counting, were performed using the 10x Genomics CellRanger 
software suite following the default parameters.  Downstream analysis of gene expression was 
performed using Seurat v.3 for R (Satija et al., 2015). Briefly, the feature-barcode matrices were 
log-normalized and top variable genes across single cells were identified using the 
FindVariableGenes function.  Data were scaled to 10,000 transcripts per cell.  Dimensionality 
reduction was performed using principal component analysis (PCA) and then the distance matrix 
was organized into a K-nearest neighbor graph (KNN), partitioned into clusters using Louvain 
algorithm, and clusters were visualized on a Uniform Manifold Approximation and Projection 
(UMAP) plot. Top differentially expressed genes for each cluster were computed and cell types 
were annotated based on expression of known markers. The Human Protein Atlas was utilized to 





Medulloblastomas can be sub-grouped using gene expression data  
 Previous publications indicate that medulloblastomas separate into four distinct 
diagnostic subtypes. In particular, a subset of 22 genes can accurately characterize 
medulloblastoma subtypes (Northcott et al., 2012). Using a subset of pediatric medulloblastoma 
tumors from our cohort, including those we studied subsequently using scRNAseq, non-
supervised hierarchical clustering analysis provided accurate subtype classification using gene 
expression data (Figure 2).  
 
 
Figure 2. Heatmap demonstrating hierarchical clustering of medulloblastoma subgroup- 
specific gene expression signatures derived from bulk RNA sequencing. Relative gene 
expression levels are indicated according to the legend, where orange indicates higher relative 
expression compared to decreased relative expression in green. Each sample has a column and is 
defined above the heatmap as belonging either to group 3 (purple), group 4 (gold), SHH (light 
green), or WNT (dark green). Bulk RNAseq results from samples studied in the thesis cohort by 
scRNA sequencing are indicated as group 3 (pink), or thesis cohort group 4 (orange).  
 
Thesis cohort (Group 3)  




Sub-typing of medulloblastomas based on scRNA sequencing 
When scRNAseq data from similar numbers of cells sequenced from a single group 3 
medulloblastoma sample, CH87, were plotted in comparison to a single group 4 
medulloblastoma sample, CH161, as shown in Figure 3, 10 distinct clusters were identified, 
many of which were sample specific. Clusters 0, 2, 4, and 7 were specific to the group 3 
medulloblastoma sample (CH87); clusters 1, 3, 5, 6, and 10 were specific to the group 4 
medulloblastoma sample (CH161); clusters 8 and 9 were shared between the two 
medulloblastoma subtypes. Genes previously identified to be specific to group 3 (Figure 4b) and 




Figure 3. UMAP representation of gene expression clusters from a group 4 versus a group 
3 medulloblastoma. a) Clustering of CH161, a group 4 medulloblastoma. b) Clustering of CH87 










Figure 4.  Expression levels of previously identified group 3- and group 4-specific genes in 
CH161 and CH87. Teal represents the expression of the analyzed marker genes in identified cell 
clusters of CH87 (group 3) and red represents the expression of the analyzed marker genes in 
identified cell clusters of CH161 (group 4) a) Expression of group 4 specific genes are plotted 





Single nuclei sequencing clustering analysis and cell type identification 
 Five brain tissue tumor samples from pediatric medulloblastomas were studied by single 
nuclei capture and sequencing (Table 1).  Our overall sequencing metrics revealed at least 3,715 
individual nuclei were sequenced for each sample and the number of sequencing reads per 
cell/nuclei resulted in similar number of genes detected per cell (Table 3). 
Gene expression data from all samples were analyzed together and clustered into 13 
groups after processing in Seurat (Figure 5). Figure 5a displays all nuclei, colored by sample 
while Figure 5b displays the 13 clusters identified during our computational processing using 
UMAP for dimensionality reduction. By analyzing the top differentially expressed genes for 
each cluster compared to all other nuclei in the dataset, one can glean information about cell 
types and gene expression phenotypes. The top differentially expressed genes for each cluster are 
listed in Table 4.  
 
Figure 5. UMAP representation of the integrated single nuclei data set. a) Clustering 






Table 4. Top five differentially expressed marker genes in scRNAseq clusters.  
 
*avg_logFC log fold-change of the average expression between the cluster vs. all other cells 
**p_val_adj adjusted p-value, based on Bonferroni correction using all genes in the dataset 
 
Cluster Gene avg_logFC* p_val_adj** Cluster Gene avg_logFC* p_val_adj** 
0 
KCNIP4 1.53938612 0 
7 
ESYT2 1.70449097 0 
DPYD 1.35681216 0 SEMA3E 1.51110781 0 
PDE1C 1.2574032 0 NTNG1 1.47652001 0 
MIR4300HG 1.18209031 0 AC092957.1 1.45478894 0 
LINC01632 1.1728838 0 NEGR1 1.44706014 0 
1 
NRG1 1.51222014 0 
8 
APOLD1 1.93534064 0 
SLC35F3 1.46712876 0 DIAPH3 1.84883511 0 
LRRTM4 1.31490884 0 TOP2A 1.56286466 0 
NLGN4Y 1.27169068 0 ASPM 1.48611701 0 
COL27A1 1.20953006 0 CENPF 1.42256865 0 
2 
CTTNBP2 1.27301983 0 
9 
PLCG2 2.0110145 4.13E-108 
GRIA2 1.17043542 0 CENPF 1.58727592 5.32E-27 
PTPRO 1.13826452 0 HSPH1 1.45021974 1.00E-117 
LINC00587 1.07644005 0 HSPA1A 1.30902929 1.26E-137 
ELP4 1.07131093 0 HIST1H2AC 1.27427086 2.24E-158 
3 
FAM19A4 1.93757924 0 
10 
NR2E3 2.21033028 0.00E+00 
AC009264.1 1.69480644 0 PTPN13 1.98060004 0 
TENM3 1.68101558 0 DISC1 1.93377412 0 
SYT1 1.67249429 0 CAMK1D 1.87211038 0 
CDH20 1.60140566 0 FKBP5 1.82298518 0 
4 
ADARB2 1.89407131 0 
11 
LRMDA 3.45642452 0 
CNTNAP2 1.71739521 0 SFMBT2 3.30195983 0 
GRIK1 1.4047383 0 SLC1A3 3.03753939 0 
CNTNAP3B 1.34340535 0 NEAT1 3.01980696 1.36E-185 
IQCJ-SCHIP1 1.31305695 2.18E-88 PLXDC2 2.96735626 2.38E-102 
5 
NTRK3 1.82287826 0 
12 
LRP1B 3.14392107 0 
GRM7 1.75361017 0 PCDH9 2.83901049 1.04E-162 
CTNNA2 1.7149246 0 KAZN 2.75793726 3.15E-153 
RIT2 1.63047899 0 ROBO2 2.59394379 1.64E-64 
PRKCE 1.43485037 0 NKAIN2 2.57743747 1.77E-168 
6 
BRIP1 1.52201886 0 
DIAPH3 1.42045159 0 
IL1RAPL1 1.38676748 0 
HELLS 1.14709102 0 
AP001347.1 1.13969168 0 
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Immune gene expression in a cohort of 121 pediatric brain tumors 
A cohort of 121 pediatric CNS tumor RNA samples were subjected to immune gene 
expression analysis using the PanCancer Immune Panel. The cohort included: 16 
medulloblastomas, 17 embryonal non-medulloblastoma tumors, 7 choroid plexus tumors, 14 
diffuse astrocytic and oligodendroglial tumors, 25 other astrocytic tumors, 7 ependymal tumors, 
3 germ cell tumors, 30 neuronal and mixed neuronal-glial tumors, and 2 tumors of the pineal 
region. For analysis, tumors were grouped into medulloblastomas (n = 16) vs. all other CNS 
tumors (n = 105). Differential expression analysis for each gene on the panel was performed to 
identify significantly differentially expressed genes within the medulloblastoma cohort. Our 
analysis revealed that several immune genes were significantly downregulated, or under 
expressed, in medulloblastomas compared to other CNS tumors (Figure 6). Some of the most 
downregulated immune genes in medulloblastomas were ITGB4, IL1RAP, KLRC2, and IL1B. 
Few immune genes were significantly overexpressed in medulloblastomas and include SMPD3, 




Figure 6. Volcano plot of immune gene expression outliers in medulloblastoma tumors 
versus other brain tumors. Gene expression values of the PanCancer immune genes in a cohort 
of medulloblastomas versus other brain tumors are plotted; each dot represents a single gene. 
The X axis displays the Log2 fold change in gene expression, and the Y axis displays the P value 
from our differential expression analysis comparing medulloblastoma tumors to other brain 
tumors. P value cut off was set at 0.05 and fold change cut off at 2. Red marker dots indicate a 
significant Log2 and p-value. Green marker dots indicate a significant fold-change value only, 
blue marker dots signify a significant p-value only, and grey marker dots are neither significant 
in fold-change nor p-value. 
 
Analysis of primary versus recurrent medulloblastoma 
 Our cohort included a primary and recurrent medulloblastoma from the same patient 
(“CH79”), with a five-year duration between the recurrence and the initial diagnosis. Clustering 
of the scRNAseq data from each tumor and gene expression-based cell type analysis revealed 
that most clusters identified for each tumor were neurons or astrocytes (Figure 7a). One cluster, 
however, reflected gene expression in monocytes/macrophages and was present only in the 
recurrent tumor sample (Figure 7b). Certain differentially expressed genes in this cluster 
indicating monocytes/macrophages include CD14, CD45, and MSR1. This cluster also appeared 
to represent other immune cells, including naïve T-cells, due to expression of PTPRC, FKBP5, 





Figure 7. UMAP representation of a primary and recurrent medulloblastoma tumor. a) cell 
type identified clusters between both primary and recurrent medulloblastomas from CH79. b) 
primary tumor gene expression-based clustering (red) versus recurrent tumor clustering (teal) of 
the two longitudinal medulloblastoma samples indicates the macrophage/monocyte cluster is 







 The characterization of medulloblastomas including different cell biology that defines 
subtypes of the disease, and its tumor microenvironment is vastly understudied. Through bulk 
RNA sequencing and scRNA sequencing, these aspects can be further defined in a robust 
manner. This work describes how characterization of the tumor microenvironment of the 
immune quiet medulloblastoma can be achieved through bulk RNA analysis and describes the 
way that scRNA sequencing can add precision to bulk RNA sequencing findings. 
 First, proper subtyping of medulloblastomas based on their RNA expression is possible. 
Bulk RNA sequencing can be utilized in the characterization of medulloblastomas, as exhibited 
in Figure 2, through gene expression-based clustering. The use of scRNA sequencing was also 
utilized in the identification of clusters and cellular expression profiles of group 3 versus group 4 
medulloblastomas. This technique can identify clusters of nuclei that are unique to or shared by 
the two groups. Figure 3 shows that CH87 (group 3) and CH161 (group 4) differ in how their 
gene expression data from nuclei are clustered, which infers differences in biology of these 
subtypes that contribute to their prognosis. This method of subtyping can be supported by 
determining whether genes that were previously identified to be specific to either group 3 or 
group 4 medulloblastomas cluster with their respective sample. These sub-group marker genes 
were highlighted in each sample in Figures 6a and 6b, demonstrating known medulloblastoma 
genes specific to group 3 are most highly expressed in CH87 and genes specific to group 4 are 
most highly expressed in CH161. These data indicate that subtyping of medulloblastomas 
through scRNA sequencing is possible and follows pathologically predicted subtyping.  With 
additional samples studied, we may be able to identify the specific biology of different cell type 
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clusters that impart known prognosis on these different subtypes, for example those cells having 
stem-like gene expression that may persist in recurrent disease. 
It is also important to note that Figure 2 begins to identify the heterogeneity of 
medulloblastomas. Two ‘outliers’ did not accurately cluster with their respective pathologically 
defined subtypes, showing that not every cancer fits into a perfectly defined set of rules and that 
cancers have a way of inventing their own expression and are biologically unique. Figure 5 aids 
in identifying unique cell populations of medulloblastomas and their expression profiles. The top 
differentially expressed genes for each cluster can be derived from these data and applied in 
many settings, such as understanding the expression profile of a certain subset of cells in a tumor 
that may not categorize well into a specific subtype of medulloblastoma.  
 Indeed, some of these unique cell clusters may represent immune cell components of the 
tumor mass.  To identify these by gene expression we studied a large number of CNS cancers 
including medulloblastomas to identify unique over- and under-expressed genes in 
medulloblastomas.  Here, gene expression analysis using the PanCancer Immune Panel yielded a 
volcano plot (Figure 6) that exhibited decreased expression of immune genes such as KLRC2, a 
gene expressed in natural killer cells, and IL1B, a gene that encodes a cytokine involved in 
inflammation. The volcano plot indicates that medulloblastomas primarily exhibit a decreased 
expression of immune genes, though a smaller population of genes were overexpressed and 
include CD24. Although CD24 modulates B-cell activation responses, there is also evidence that 
it is highly expressed in developing pediatric brain (Reactome). From these data, one can begin 
characterizing the immune cell content of medulloblastomas as low compared to other CNS 
tumors. Through the scRNA sequencing of longitudinal samples, namely primary versus 
recurrent medulloblastomas, this characterization can be further refined. Figure 7b indicates 
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differing cell expression profiles between a primary and recurrent medulloblastoma from the 
same patient. Notably, the recurrent medulloblastoma of CH79 differentially expresses CD14, 
CD45, and MSR1 which are indicators of monocytes/macrophages. This may indicate that 
immune infiltration of monocytes/macrophages is higher in recurrent medulloblastomas, which 
can only be substantiated by single cell analyses of additional primary/recurrent pairs due to the 
low level of infiltration evidenced.  
 Through characterization of the tumor microenvironment and expression profile of 
different cell types present in medulloblastomas, as well as the comparison of the expression 
profile between different subtypes and primary versus recurrent tumors, better outcomes for 
medulloblastoma patients could be possible in the future. Looking forward, future clinical 
research ought to include immunotherapies that act to recruit immune cells into the 
microenvironment, such as oncolytic virotherapy given these findings of relatively low immune 
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